142 related articles for article (PubMed ID: 11602824)
1. Interplay between inhibition of adenosine uptake and phosphodiesterase type 3 on cardiac function by cilostazol, an agent to treat intermittent claudication.
Wang S; Cone J; Fong M; Yoshitake M; Kambayashi Ji ; Liu Y
J Cardiovasc Pharmacol; 2001 Nov; 38(5):775-83. PubMed ID: 11602824
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the effects of cilostazol and milrinone on intracellular cAMP levels and cellular function in platelets and cardiac cells.
Cone J; Wang S; Tandon N; Fong M; Sun B; Sakurai K; Yoshitake M; Kambayashi J; Liu Y
J Cardiovasc Pharmacol; 1999 Oct; 34(4):497-504. PubMed ID: 10511123
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the effects of cilostazol and milrinone on cAMP-PDE activity, intracellular cAMP and calcium in the heart.
Shakur Y; Fong M; Hensley J; Cone J; Movsesian MA; Kambayashi J; Yoshitake M; Liu Y
Cardiovasc Drugs Ther; 2002 Sep; 16(5):417-27. PubMed ID: 12652111
[TBL] [Abstract][Full Text] [Related]
4. Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake.
Liu Y; Shakur Y; Yoshitake M; Kambayashi Ji J
Cardiovasc Drug Rev; 2001; 19(4):369-86. PubMed ID: 11830753
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of adenosine uptake and augmentation of ischemia-induced increase of interstitial adenosine by cilostazol, an agent to treat intermittent claudication.
Liu Y; Fong M; Cone J; Wang S; Yoshitake M; Kambayashi J
J Cardiovasc Pharmacol; 2000 Sep; 36(3):351-60. PubMed ID: 10975593
[TBL] [Abstract][Full Text] [Related]
6. Identification of interaction sites of cyclic nucleotide phosphodiesterase type 3A with milrinone and cilostazol using molecular modeling and site-directed mutagenesis.
Zhang W; Ke H; Colman RW
Mol Pharmacol; 2002 Sep; 62(3):514-20. PubMed ID: 12181427
[TBL] [Abstract][Full Text] [Related]
7. Cilostazol increases tissue blood flow in contracting rabbit gastrocnemius muscle.
Fong M; Yoshitake M; Kambayashi J; Liu Y
Circ J; 2010 Jan; 74(1):181-7. PubMed ID: 19966507
[TBL] [Abstract][Full Text] [Related]
8. Cilostazol, an inhibitor of type 3 phosphodiesterase, produces endothelium-independent vasodilation in pressurized rabbit cerebral penetrating arterioles.
Nakamura K; Ikomi F; Ohhashi T
J Vasc Res; 2006; 43(1):86-94. PubMed ID: 16286783
[TBL] [Abstract][Full Text] [Related]
9. New milrinone analogues: in vitro study of structure-activity relationships for positive inotropic effect, antagonism towards endogenous adenosine, and inhibition of cardiac type III phosphodiesterase.
Floreani M; Fossa P; Gessi S; Mosti L; Borea PA; Dorigo P
Naunyn Schmiedebergs Arch Pharmacol; 2003 Feb; 367(2):109-18. PubMed ID: 12595951
[TBL] [Abstract][Full Text] [Related]
10. Effects of cilostazol, a selective cyclic AMP phosphodiesterase inhibitor on isolated rabbit spinal arterioles.
Yashiro Y; Ohhashi T
Jpn J Physiol; 2002 Oct; 52(5):471-7. PubMed ID: 12533252
[TBL] [Abstract][Full Text] [Related]
11. Cilostazol, an inhibitor of type 3 phosphodiesterase, stimulates large-conductance, calcium-activated potassium channels in pituitary GH3 cells and pheochromocytoma PC12 cells.
Wu SN; Liu SI; Huang MH
Endocrinology; 2004 Mar; 145(3):1175-84. PubMed ID: 14645120
[TBL] [Abstract][Full Text] [Related]
12. Cilostazol and dipyridamole synergistically inhibit human platelet aggregation.
Liu Y; Cone J; Le SN; Fong M; Tao L; Shoaf SE; Bricmont P; Czerwiec FS; Kambayashi J; Yoshitake M; Sun B
J Cardiovasc Pharmacol; 2004 Aug; 44(2):266-73. PubMed ID: 15243309
[TBL] [Abstract][Full Text] [Related]
13. 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2-(1H)quinolinone (cilostazol), a phosphodiesterase type 3 inhibitor, reduces infarct size via activation of mitochondrial Ca2+-activated K+ channels in rabbit hearts.
Fukasawa M; Nishida H; Sato T; Miyazaki M; Nakaya H
J Pharmacol Exp Ther; 2008 Jul; 326(1):100-4. PubMed ID: 18381926
[TBL] [Abstract][Full Text] [Related]
14. Thrombin regulates intracellular cyclic AMP concentration in human platelets through phosphorylation/activation of phosphodiesterase 3A.
Zhang W; Colman RW
Blood; 2007 Sep; 110(5):1475-82. PubMed ID: 17392505
[TBL] [Abstract][Full Text] [Related]
15. [Research and development of cilostazol: an antiplatelet agent].
Nishi T; Kimura Y; Nakagawa K
Yakugaku Zasshi; 2000 Dec; 120(12):1247-60. PubMed ID: 11193377
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of shear stress-induced platelet aggregation by cilostazol, a specific inhibitor of cGMP-inhibited phosphodiesterase, in vitro and ex vivo.
Minami N; Suzuki Y; Yamamoto M; Kihira H; Imai E; Wada H; Kimura Y; Ikeda Y; Shiku H; Nishikawa M
Life Sci; 1997; 61(25):PL 383-9. PubMed ID: 9416770
[TBL] [Abstract][Full Text] [Related]
17. Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor on the contraction of vascular smooth muscle.
Tanaka T; Ishikawa T; Hagiwara M; Onoda K; Itoh H; Hidaka H
Pharmacology; 1988; 36(5):313-20. PubMed ID: 2841693
[TBL] [Abstract][Full Text] [Related]
18. New mechanism of action for cilostazol: interplay between adenosine and cilostazol in inhibiting platelet activation.
Sun B; Le SN; Lin S; Fong M; Guertin M; Liu Y; Tandon NN; Yoshitake M; Kambayashi J
J Cardiovasc Pharmacol; 2002 Oct; 40(4):577-85. PubMed ID: 12352320
[TBL] [Abstract][Full Text] [Related]
19. Functional and biochemical evidence for diazepam as a cyclic nucleotide phosphodiesterase type 4 inhibitor.
Collado MC; Beleta J; Martinez E; Miralpeix M; Domènech T; Palacios JM; Hernández J
Br J Pharmacol; 1998 Mar; 123(6):1047-54. PubMed ID: 9559885
[TBL] [Abstract][Full Text] [Related]
20. Differential effect of phosphodiesterase-3 inhibitors on sympathetic hyperinnervation in healed rat infarcts.
Lee TM; Lin SZ; Chang NC
Circ J; 2014; 78(2):366-76. PubMed ID: 24304537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
